Revenue segments as reported by the company.

Net product sales

Alliance and other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Marketing, selling and administrative

Research and development

IPRD charge - MyoKardia acquisition

Amortization of acquired intangible assets

Other (income)/ expense, net

Acquired IPRD

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Bristol-Myers

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers chemically-synthesized drugs or small molecules and products produced from biological processes called biologics. The company was founded in August 1933 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Bristol-Myers reports robust 2022 performance and outlines growth strategies

Bristol-Myers Squibb delivered strong financial performance in 2022, with revenue growth and key product successes driving sales to $46 billion.
The company's strategic focus on portfolio expansion, market access enhancement, and operational efficiency positions it for continued growth and value creation.
Challenges around market access, legislative impacts, and expense management require strategic attention, while opportunities in product development and market expansion offer avenues for future growth.

Bristol-Myers reports robust Q1 earnings, eyes growth amid challenges

Bristol-Myers' Q1 2023 performance reflects strong sales growth and a focus on innovation, with significant progress in pipeline development and new product launches.
While facing challenges from generic competition and operational issues, the company is well-positioned to capitalize on industry advancements and strategic opportunities for growth.
By reaffirming guidance, emphasizing strategic alignment, and pursuing new therapies, Bristol-Myers demonstrates resilience and a commitment to long-term success in the pharmaceutical market.

Bristol-Myers reports robust Q2 sales and strategic growth initiatives

Bristol-Myers' Q2 performance showcased strong sales driven by new product growth and key product successes like Opdivo and Reblozyl.
While facing challenges with certain products and revenue guidance changes, the company remains confident in its financial commitments and growth outlook.
Opportunities lie in capacity ramp-up for key products, conversion strategies for patient assistance programs, and upcoming R&D insights.
Overall, Bristol-Myers' performance, strengths, and opportunities position the company for continued growth and success in the pharmaceutical market.

Bristol-Myers reports robust Q3 performance, eyes growth opportunities

Bristol-Myers Squibb's Q3 earnings call highlighted strong performance, strategic initiatives for growth, and confidence in future prospects. Despite challenges in product performance and reimbursement, the company is optimistic about market improvements and growth opportunities. Executives are focused on driving sustainable long-term growth and expanding their product portfolio.

Bristol-Myers reports robust Q4 earnings, eyes growth through strategic initiatives

Bristol-Myers' Q4 2023 showcased strong financial performance, strategic advancements, and a focus on growth drivers like Opdivo and new launches.
Despite challenges in negotiations and market dynamics, Bristol-Myers remains poised for growth through its robust product portfolio and business development strategies.
The company's emphasis on innovation, commercial execution, and clinical progress positions Bristol-Myers for sustained growth and market leadership in the pharmaceutical industry.

Bristol-Myers meets Q1 expectations, focuses on growth opportunities

Bristol-Myers Squibb's Q1 performance met expectations with strong sales growth driven by key brands and strategic acquisitions.
Despite challenges in operating expenses and interest costs impacting income, the focus on efficiency and cost savings remains a priority.
The company's strengths lie in robust sales growth of key brands, promising pipeline advancements, and strategic capital allocation plans.
Opportunities in expanding indications, new trials, and market launches position Bristol-Myers for long-term growth and competitive advantage.

Bristol-Myers reports strong Q2 performance, bullish on pipeline growth

Bristol-Myers (BMY) showcased a robust Q2 performance, emphasizing pipeline advancements and strategic capital allocation for growth and returns.
The company is confident in navigating pricing changes and improving access dynamics for key products, while focusing on transformative medicines and operational excellence.
With a positive outlook for the year, Bristol-Myers is poised to leverage opportunities in oncology, pipeline advancements, and expanding indications for key assets.

Bristol-Myers (BMY) reports strong Q3 sales and pipeline progress

Bristol-Myers Squibb (BMY) showcased robust performance with strong sales growth and positive clinical data for pipeline programs.
The company's strategic strengths lie in operational excellence, capital allocation, and commitment to sustainable growth and innovation.
Challenges include market dynamics, competition in heart failure drugs, and translating clinical data into successful drug programs.
Opportunities abound in the growing heart failure drugs market, upcoming trial data readouts, and continued focus on portfolio growth and operational efficiency.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies. The company was founded in August 1933 and is headquartered in Princeton, NJ.

Bristol Myers' (BMY) late-stage study evaluating Opdivo in combination with Yervoy as a first-line treatment for squamous cell carcinoma of the head and neck fails to meet goal.

Bristol Myers' (BMY) Opdivo+Yervoy Fails First-Line SCCHN Study

Bristol Myers Squibb (BMY) closed the most recent trading day at $67.30, moving -0.19% from the previous trading session.

Bristol Myers Squibb (BMY) Stock Moves -0.19%: What You Should Know

Bristol Myers Squibb & Co's (NYSE: BMY) Phase 3 CheckMate -651 data evaluating Opdivo (nivolumab) plus Yervoy (ipilimumab) combo in head and neck cancer failed to primary endpoints of the trial.  The trial assessed Opdivo plus Yervoy combination to Extreme regimen (cetuximab, cisplatin/carboplatin, and fluorouracil) as a first-line treatment in platinum-eligible patients with recurrent or metastatic squamous cell carcinoma of the head and neck.

Bristol-Myers' Opdvio/Yervoy Combo Therapy Flunks In Head & Neck Cancer Trial

Bristol Myers Squibb Co. said Friday a late-stage study of a treatment for head and neck cancer failed to meet its main goals. The Phase 3 trial sought to compare Opdivo plus Yervoy to the EXTREME regimen (cetuximab, cisplatin/carboplatin and fluorouracil) as a first-line treatment in platinum-eligible patients with recurrent or metastatic squamous cell carcinoma of the head and neck.

Bristol Myers says late-stage trial of head and neck cancer treatment failed to meet main goals

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #CheckMate--BMS Provides Update on CheckMate -651

Bristol Myers Squibb Provides Update on CheckMate -651 Trial Evaluating Opdivo (nivolumab) Plus Yervoy (ipilimumab) Versus EXTREME Regimen as First-Line Treatment for Squamous Cell Carcinoma of the Head and Neck

AbbVie

American Express

Bank of New York Mellon

Chevron

Globe Life Inc

Kraft Heinz

Coca-Cola

Mastercard

Merck

Sirius XM Holdings Inc

STORE Capital

U.S. Bancorp

Verizon

This Buffett holdings list from Kiplinger first appeared 5/17/21 on line. YCharts and Dogs of The Dow also track this Buffett/Berkshire Batch. Here is your update from 7/13/21 YCharts data. 8 of 46 current Berkshire Hathaway owned stocks pay dividends. As of 7/13/21 the top ten ranged 2.72%-5.16% by annual yield and ranged 19.87%-67.17% per broker estimated price target upsides.

Buffett 46 July Holdings Include 28 Dividend Payers

Alerian MLP ETF

Goldman Sachs BDC

Global X MLP & Energy Infrastructure ETF

Medical Properties Trust

ONEOK

Pfizer

Global X Russell 2000 Covered Call ETF

After 19 weeks and $1,900, the Dividend Harvesting Portfolio is generating $122.02 in estimated annual income and $10.37 in monthly estimated income. In week 19, I started a position in Goldman Sachs BDC Inc while adding an additional share of Medical Property Trust and RYLD & MPLX from Global X.

Dividend Harvesting: Week 19 Update, $1,900 Invested, 39 Positions, $122.02 In Annual Dividends

Bristol Myers Squibb (BMY) closed at $66.69 in the latest trading session, marking a -0.67% move from the prior day.

Bristol Myers Squibb (BMY) Stock Moves -0.67%: What You Should Know

Bristol-Myers (BMY) maintains momentum on new drug approvals despite some key established drugs facing challenges.

Bristol-Myers (BMY) Gains 7.6% YTD: What to Expect in 2H

The battle for market share could come down to which drug has the lesser side effects.

Can Gilead Beat Bristol Myers Squibb With Its Cancer CAR-T Therapy?

Bristol-Myers Squibb stock appears ready for a new valuation and trading range, where the low to mid $60s should provide support.

Bristol-Myers Squibb Is A High Yielding Blue-Chip That Should Appreciate

Agenus

Shares of Agenus Inc. were up 2.0% in premarket trading on Tuesday after the company said a licensing deal with Bristol Myers Squibb Co. had closed. As part of the agreement, Bristol plans to study an experimental Agenus immuno-oncology drug as a treatment for non-small cell lung cancer.

Agenus says its Bristol Myers Squibb licensing deal has up to $1.3 billion in milestone payments

Bristol-Myers Squibb Co (NYSE:BMY) is a global biopharmaceutical company that focuses on the discovery, development, and delivery of medications.

BMY Looks to Launch Higher After Cancer Treatment Approval

Johnson & Johnson

Fierce Pharma reported RBC Capital Markets said a nearly 10% drop in biotech stocks for the first six months of the year could ignite a bonanza of second-half deals.

Merck, Johnson & Johnson and Bristol-Myers Seen as Most Active in M&A

The Dow Jones rose 170 points, the S&P 500 ticked up 0.1%, and the tech-heavy Nasdaq slipped 0.1%. Find opportunities in this market with today's Top Buys from Q.ai's artificial intelligence.

Bristol-Myers Squibb Co Ranked Among Today's Top Buys

bluebird bio

Gilead Sciences

Legend Biotech

Legend Biotech's CAR-T therapy's trial results were amazing, and could earn the treatment FDA approval in 2021.

Will This 2020 Biotech IPO Crush the Market This Year?

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #MEDIA--BMS Receives EU Approval for Opdivo+Yervoy for the Treatment of MRD or Microsatellite Instability–High Metastatic Colorectal Cancer After Prior Chemo

Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) Plus Yervoy (ipilimumab) for the Treatment of Mismatch Repair Deficient or Microsatellite Instability–High Metastatic Colorectal Cancer After Prior Chemotherapy

Bristol Myers (BMY) obtains positive CHMP opinion for cell immunotherapy, Abecma, for multiple myeloma and Opdivo for the indication of gastroesophageal junction cancer.

Bristol Myers (BMY) Gets Positive CHMP Opinion for Abecma

Air Products and Chemicals

Comcast

Cisco Systems

General Dynamics

Illinois Tool Works

Stryker

This article series presents upcoming ex-dividend dates. We provide a summary table with relevant data and key statistics, including the next payout and pay date.

Upcoming Ex-Dividend Dates: June 29-July 12, 2021

Amazon

Bank of America

Teva Pharmaceutical

These growth and value stocks are begging to be bought by investors.

5 Buffett Stocks to Buy Hand Over Fist for the Second Half of 2021

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #MEDIA--BMS Receives Positive CHMP Opinion for Opdivo as Adjuvant Treatment for Esophageal or Gastro Junction Cancer Patients w/ RPD Following Chemo

Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo (nivolumab) as Adjuvant Treatment for Esophageal or Gastroesophageal Junction Cancer Patients with Residual Pathologic Disease Following Chemoradiotherapy

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #Abecma--Bristol Myers Squibb Receives Positive CHMP Opinion for Anti-BCMA CAR T Cell Therapy Abecma for Relapsed and Refractory Multiple Myeloma

Bristol Myers Squibb Receives Positive CHMP Opinion for Anti-BCMA CAR T Cell Therapy Abecma (idecabtagene vicleucel) for Relapsed and Refractory Multiple Myeloma

Hess

Microsoft

Oceaneering

Revolve

Stitch Fix

Shopify

Exxon Mobil

The Fed could begin raising rates sooner than 2023. Healthcare and utilities are climbing our sector ranking.

The Fed Has Spoken: Stocks To Buy Now

Bristol Myers (BMY) wins approval for acute myeloid leukemia drug, Onureg, in the European Union.

Bristol Myers' (BMY) Onureg Gets European Commission Approval

JPMorgan Chase & Co

Medtronic

T. Rowe Price Group

We provide a summary of upcoming ex-dividend dates in a quick reference table. The table includes relevant data and key statistics as well as the next payout and pay date.

News for Bristol-Myers Stock (BMY)